Log In
Print this Print this

PF-04523655, PF-655, RTP801I-14

Also known as: formerly PF-4523655

  Manage Alerts
Collapse Summary General Information
Company SBI Biotech Co. Ltd.
DescriptionShort interfering RNA (siRNA) that inhibits the expression of RTP801
Molecular Target DNA-damage-inducible transcript 4 (DDIT4) (RTP801) (REDD1)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetic macular edema (DME)
Indication DetailsImprove visual acuity in patients with diabetic macular edema (DME)
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today